scholarly journals Daptomycin Failure for Treatment of Pulmonary Septic Emboli in Native Tricuspid and Mitral Valve Methicillin-ResistantStaphylococcus aureusEndocarditis

2013 ◽  
Vol 2013 ◽  
pp. 1-4
Author(s):  
Hadeel Zainah ◽  
Marcus Zervos ◽  
Wassim Stephane ◽  
Sara Chamas Alhelo ◽  
Ghattas Alkhoury ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Mitral Valve ◽  
Treatment Failure ◽  
Native Valve ◽  
Methicillin Resistant ◽  
Septic Emboli ◽  
Native Valve Endocarditis ◽  
Pulmonary Infiltrates ◽  
Sole Agent

Daptomycin has been used with success for the treatment of right-sided methicillin-resistantStaphylococcus aureus(MRSA) endocarditis. However, its efficacy has not been completely assessed for the treatment of MRSA endocarditis when it is associated with pulmonary septic emboli. Hereby, we present a case of MRSA mitral and tricuspid native valve endocarditis with pulmonary septic emboli, which was treated with daptomycin as a sole agent, resulting in worsening pulmonary infiltrates and treatment failure.

scholarly journals High-Dose Daptomycin plus Fosfomycin Is Safe and Effective in Treating Methicillin-Susceptible and Methicillin-Resistant Staphylococcus aureus Endocarditis

2012 ◽  
Vol 56 (8) ◽  
pp. 4511-4515 ◽  
Author(s):  
José M. Miró ◽  
José M. Entenza ◽  
Ana del Río ◽  
Maria Velasco ◽  
Ximena Castañeda ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Methicillin Resistant Staphylococcus Aureus ◽  
High Dose ◽  
Native Valve ◽  
Methicillin Resistant ◽  
Content Type ◽  
Native Valve Endocarditis ◽  
Prosthetic Aortic Valve ◽  
Staphylococcus Aureus Endocarditis

ABSTRACTWe describe 3 patients with left-sided staphylococcal endocarditis (1 with methicillin-susceptibleStaphylococcus aureus[MSSA] prosthetic aortic valve endocarditis and 2 with methicillin-resistantS. aureus[MRSA] native-valve endocarditis) who were successfully treated with high-dose intravenous daptomycin (10 mg/kg/day) plus fosfomycin (2 g every 6 h) for 6 weeks. This combination was testedin vitroagainst 7 MSSA, 5 MRSA, and 2 intermediately glycopeptide-resistantS. aureusisolates and proved to be synergistic against 11 (79%) strains and bactericidal against 8 (57%) strains. This combination deserves further clinical study.

scholarly journals Multicenter Cohort Study of Ceftaroline versus Daptomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infection

2021 ◽  
Author(s):  
Evan J Zasowski ◽  
Trang D Trinh ◽  
Kimberly C Claeys ◽  
Abdalhamid M Lagnf ◽  
Sahil Bhatia ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Cohort Study ◽  
Treatment Failure ◽  
Methicillin Resistant Staphylococcus Aureus ◽  
Study Drug ◽  
Bloodstream Infections ◽  
Risk Difference ◽  
Multicenter Cohort Study ◽  
Methicillin Resistant ◽  
Composite Failure

Abstract Background Observational data suggest ceftaroline may be effective for methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections (BSI) but comparative data with standard of care are limited. This analysis compares the outcomes of MRSA BSI treated with ceftaroline or daptomycin. Methods Multicenter, retrospective, observational cohort study of adult patients with MRSA BSI from 2010 to 2017. Patients treated with ≥ 72 hours of ceftaroline or daptomycin were included. Those clearing BSI before study drug and those with a pneumonia source were excluded. The primary outcome was composite treatment failure, defined as 30-day mortality, BSI duration ≥ 7 days on study drug, and 60-day MRSA BSI recurrence. Inverse probability of treatment weighted risk difference in composite failure between daptomycin and ceftaroline groups was computed and 15% non-inferiority margin applied. Results Two hundred seventy patients were included; 83 ceftaroline and 187 daptomycin. Ceftaroline was non-inferior to daptomycin with respect to composite failure [39% daptomycin, 32.5% ceftaroline; weighted risk difference (95% CI) 7.0% (-5.0 – 19.0%)]. No differences between treatment groups was observed for 30-day mortality or other secondary efficacy outcomes. Creatine phosphokinase elevation was significantly more common among daptomycin patients (5.3% vs 0%, P = 0.034). Rash was significantly more common among ceftaroline patients (10.8 vs 1.1%, P = 0.001). Conclusions No difference in treatment failure or mortality was observed between MRSA BSI treated with ceftaroline or daptomycin. These data support future study of ceftaroline as a primary MRSA BSI treatment and current use of ceftaroline when an alternative to vancomycin and daptomycin is required.

scholarly journals Lifesaving Treatment of Aortic Valve Staphylococcus aureus Endocarditis: Daptomycin and Early Surgical Therapy

2020 ◽  
Author(s):  
Can Yilmaz Yozgat ◽  
Selcuk Uzuner ◽  
Yasin Ay ◽  
Hafize Otcu Temur ◽  
Burcu Bursal Duramaz ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Aortic Valve ◽  
Surgical Therapy ◽  
Initial Therapy ◽  
Native Valve ◽  
Aureus Infection ◽  
Native Valve Endocarditis ◽  
Septic Embolization ◽  
Recommended Treatment ◽  
Severe Infections

AbstractInfective endocarditis (IE) is an uncommon infection in children. The recommended treatment for native valve endocarditis secondary to methicillin-susceptible Staphylococcus aureus infection is antistaphylococcal penicillins such as nafcillin or oxacillin. If the initial therapy fails in IE, it can lead to catastrophic results. Nowadays, daptomycin is the best alternative antimicrobial agent to treat children with severe infections, when standard antimicrobial therapy does not yield a result. Herein, we describe a case of a 16-year-old boy who had aortic valve S. aureus endocarditis with septic embolization and stroke. The patient was successfully treated only with daptomycin as well as surgical therapy in the early phase of the infection.

Sign in / Sign up

Export Citation Format

Share Document